2-氟-5-(三氟甲氧基)苯胺 | 116369-23-4

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-氟-5-(三氟甲氧基)苯胺
• 中文别名: 2-氟-3-(三氟甲氧基)苯胺
• 英文名称: 2-fluoro-5-(trifluoromethoxy)aniline
• CAS: 116369-23-4
• 化学式: C₇H₅F₄NO
• mdl: MFCD09832254
• 分子量: 195.116
• InChiKey: HQUWXEXDIIWBBY-UHFFFAOYSA-N

物化性质

• 沸点：
  190.5±35.0 °C(Predicted)
• 密度：
  1.431±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 危险等级：
  6.1
• 海关编码：
  2922299090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P261,P280,P305+P351+P338,P310
• 危险品运输编号：
  2810
• 危险性描述：
  H302,H311,H315,H319,H332
• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Fluoro-5-(trifluoromethoxy)aniline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H311: Toxic in contact with skin
H302: Harmful if swallowed
H332: Harmful if inhaled
H315: Causes skin irritation
Causes serious eye irritation
H319:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P309: IF exposed or you feel unwell:
P310: Immediately call a POISON CENTER or doctor/physician
P302+P352: IF ON SKIN: Wash with soap and water

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Fluoro-5-(trifluoromethoxy)aniline
CAS number: 116369-23-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H5F4NO
Molecular weight: 195.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN2810 Class: 6.1 Packing group: III
Proper shipping name: TOXIC, LIQUIDS, ORGANIC, N.O.S. OR TOXIC, LIQUIDS, ORGANIC, N.O.S. INHALA-
TION HAZARD, PACKING GROUP I, ZONE A OR B (2-Fluoro-5-(trifluoromethoxy)aniline)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氟-5-(三氟甲氧基)苯胺 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 吡啶 、 仲丁基锂 、 三乙胺 、 potassium hydroxide 作用下， 以 四氢呋喃 、 环己烷 、 二甲基亚砜 、 叔丁醇 为溶剂， 反应 3.67h， 生成 7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1H-indole
  参考文献：
  名称：

  [EN] SPIROPIPERIDINE BENZYLAMINES AS BETA-TRYPTASE INHIBITORS
  [FR] SPIROPIPÉRIDINE BENZYLAMINESUTILES COMME INHIBITRICES DE LA BÊTA-TRYPTASE

  摘要：

  本发明公开并声明了一系列式(I)的取代螺环哌啶苄胺化合物，其中R如本文所述。更具体地说，本发明的化合物是β-色胺酶的抑制剂，因此可用作治疗关节炎，包括关节炎、类风湿关节炎和其他关节炎症状，如类风湿脊柱炎、痛风性关节炎、创伤性关节炎、风疹性关节炎、银屑病性关节炎、骨关节炎或其他慢性炎症性关节疾病，或关节软骨破坏疾病、眼结膜炎、春季结膜炎、炎性肠病、哮喘、过敏性鼻炎、间质性肺病、纤维化、硬皮病、肺纤维化、肝硬化、心肌纤维化、神经纤维瘤、肥厚性瘢痕、各种皮肤病症，例如特应性皮炎和银屑病、心肌梗死、中风、心绞痛或动脉粥样硬化斑块破裂的其他后果，以及牙周病、糖尿病视网膜病变、黄斑变性、急性黄斑变性、湿性黄斑变性、肿瘤生长、过敏反应、多发性硬化、消化性溃疡或合胞病毒感染的药物。

  公开号：

  WO2011079103A1
• 作为产物：
  描述：

  2,4-二氟-3-三氟甲基溴苯 生成 2-氟-5-(三氟甲氧基)苯胺
  参考文献：
  名称：

  MARHOLD ALBRECHT

  摘要：

  DOI：

文献信息

• [EN] alpha7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-I<br/>[FR] MODULATEURS DU RÉCEPTEUR Alpha7 NICOTINIQUE D'ACÉTYLCHOLINE ET LEURS UTILISATIONS
  申请人：BIONOMICS LTD

  公开号：WO2014019023A1

  公开（公告）日：2014-02-06

  The present invention relates to chemical compounds of formula (I), with the substituents as described in the specification, useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (α7 nAChR). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of α7 nAChR is advantageous, including neurodegenerative and neuropsychiatric diseases and also neuropathic pain and inflammatory diseases.

  本发明涉及化学式（I）的化合物，其取代基如规范中所述，在正向调节α7尼古丁乙酰胆碱受体（α7 nAChR）中有用。该发明还涉及这些化合物在治疗或预防广泛范围的疾病中的应用，其中正向调节α7 nAChR是有利的，包括神经退行性和神经精神疾病，以及神经病性疼痛和炎症性疾病。
• Discovery of BNC375, a Potent, Selective, and Orally Available Type I Positive Allosteric Modulator of α7 nAChRs
  作者：Andrew J. Harvey、Thomas D. Avery、Laurent Schaeffer、Christophe Joseph、Belinda C. Huff、Rajinder Singh、Christophe Morice、Bruno Giethlen、Anton A. Grishin、Carolyn J. Coles、Peter Kolesik、Stéphanie Wagner、Emile Andriambeloson、Bertrand Huyard、Etienne Poiraud、Dharam Paul、Susan M. O’Connor

  DOI：10.1021/acsmedchemlett.9b00001

  日期：2019.5.9

  whereas Type II PAMs both increase channel response and delay receptor desensitization. Both Type I and Type II PAMs are reported in literature, but there are limited reports describing their structure-kinetic profile relationships. Here, we report a novel class of compounds with either Type I or Type II behavior that can be tuned by the relative stereochemistry around the central cyclopropyl ring: for example

  就其对通道动力学的影响而言，α7nAChRs的正变构调节剂（PAM）可能具有不同的特性。I型PAM会放大对乙酰胆碱的峰通道响应，但似乎不会影响通道脱敏动力学，而II型PAM会增加通道响应并延迟受体脱敏。I型和II型PAM均在文献中进行了报道，但很少有报道描述它们的结构动力学轮廓关系。在这里，我们报告了一类具有I型或II型行为的新型化合物，可以通过围绕中央环丙基环的相对立体化学进行调节：例如（R，R）-13（BNC375）及其具有RR立体化学的类似物I型PAM位于中央环丙基环周围，而具有SS立体化学的同一系列化合物（例如，（S，S）-13）是使用膜片钳电生理学测量的II型PAM。通过改变苯胺环上的取代基可实现对动力学的进一步精细控制：通常，苯胺被强吸电子基团取代会降低这些化合物的II型特性。我们通过结构活性优化工作发现了BNC375，这是一种具有良好CNS-药物样性质和临床候选潜力的小分子。
• HEPATITIS C VIRUS INHIBITORS
  申请人：LONG Daniel D.

  公开号：US20130115194A1

  公开（公告）日：2013-05-09

  The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

  这项发明提供了式(I)的化合物： 其中变量在规范中定义，或其药用盐，这些化合物是乙型肝炎病毒复制的抑制剂。该发明还提供了包括这些化合物的药物组合物，使用这些化合物治疗乙型肝炎病毒感染的方法，以及用于制备这些化合物的工艺和中间体。
• Imidazo[1,2-a]quinoxalines for melanoma treatment with original mechanism of action
  作者：Cindy Patinote、Carine Deleuze-Masquéfa、Kamel Hadj Kaddour、Laure-Anaïs Vincent、Romain Larive、Zahraa Zghaib、Jean-François Guichou、Mona Diab Assaf、Pierre Cuq、Pierre-Antoine Bonnet

  DOI：10.1016/j.ejmech.2020.113031

  日期：2021.2

  incidence has regularly increased over the past decades. We described here the preparation of new compounds based on the 1-(3,4-dihydroxyphenyl)imidazo[1,2-a]quinoxaline structure. Different positions of the quinoxaline moiety were screened to introduce novel substituents in order to study their influence on the biological activity. Several alkylamino or alkyloxy groups were also considered to replace

  黑色素细胞的恶性转化每年导致数千人死亡，这使黑色素瘤成为重要的公共卫生问题。黑色素瘤是最具有侵略性的皮肤癌，在过去的几十年中，其发病率定期增加。我们在这里描述了基于1-（3,4-二羟基苯基）咪唑并[1,2- a ]喹喔啉结构的新化合物的制备。筛选喹喔啉部分的不同位置以引入新的取代基，以研究其对生物活性的影响。还考虑了几个烷基氨基或烷氧基取代我们第一代咪喹啉的甲胺。咪唑[1,2- a]吡嗪衍生物也被设计为潜在的最小结构。对A375黑色素瘤细胞的研究显示出有趣的体外低纳摩尔细胞毒活性。其中，9d（EAPB02303）特别引人注目，因为它的功效比维拉非尼（用于BRAF突变黑素瘤的参考临床疗法）高20倍。与第一代产品相反，EAPB02303不会抑制微管蛋白的聚合，这一点已通过体外试验和分子模型研究证实。转录组分析突出显示的EAPB02303的作用机制与一组12种著名的抗癌药物明显不同。体内 EAPB02303
• [EN] DISUBSTITUTED [4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-1H-INDOL-3-YL]-METHANONES<br/>[FR] [4-(5-AMINOMÉTHYL-PHÉNYL)-PIPÉRIDIN-1-YL]-1H-INDOL-3-YL]-MÉTHANONES DISUBSTITUÉES
  申请人：SANOFI AVENTIS

  公开号：WO2011022449A1

  公开（公告）日：2011-02-24

  The present invention extends to the compound of formula I: or a prodrug, pharmaceutically acceptable salt, or solvate of said compound. Furthermore, the present invention is directed to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula I, and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed to the use of a compound of formula I as an inhibitor of tryptase, comprising introducing the compound into a composition comprising tryptase. In addition, the present invention is directed to the use of a compound of formula I for treating a patient suffering from, or subject to, a physiological condition in need of amelioration of an inhibitor of tryptase comprising administering to the patient a therapeutically effective amount of the compound of Claim 1. The present invention is directed also to the preparation of a compound of formula I.

  本发明涉及到式I的化合物：或者该化合物的前药、药用可接受的盐或溶剂。此外，本发明涉及一种包括式I化合物的药物组合物，以及药用可接受的载体的药学有效量。此外，本发明涉及将式I化合物用作色氨酸蛋白酶抑制剂的用途，包括将该化合物引入含有色氨酸蛋白酶的组合物中。此外，本发明还涉及将式I化合物用于治疗患有或患有需要改善色氨酸蛋白酶抑制剂的生理状况的患者的用途，包括向患者施用权利要求1中的化合物的治疗有效量。本发明还涉及制备式I化合物。